BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 18473731)

  • 21. Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression.
    Sin JI
    Immunology; 2009 Sep; 128(1 Suppl):e707-17. PubMed ID: 19740332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
    Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
    Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.
    Jindra C; Huber B; Shafti-Keramat S; Wolschek M; Ferko B; Muster T; Brandt S; Kirnbauer R
    PLoS One; 2015; 10(9):e0138722. PubMed ID: 26381401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.
    Paz De la Rosa G; Monroy-García A; Mora-García Mde L; Peña CG; Hernández-Montes J; Weiss-Steider B; Gómez-Lim MA
    Virol J; 2009 Jan; 6():2. PubMed ID: 19126233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B surface antigen fusions delivered by DNA vaccination elicit CTL responses to human papillomavirus oncoproteins associated with tumor protection.
    Haigh O; Kattenbelt J; Cochrane M; Thomson S; Gould A; Tindle R
    Cancer Gene Ther; 2010 Oct; 17(10):708-20. PubMed ID: 20539319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.
    Jemon K; Young V; Wilson M; McKee S; Ward V; Baird M; Young S; Hibma M
    PLoS One; 2013; 8(6):e66866. PubMed ID: 23799135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice.
    Bahrami AA; Ghaemi A; Tabarraei A; Sajadian A; Gorji A; Soleimanjahi H
    J Virol Methods; 2014 Sep; 206():12-8. PubMed ID: 24880067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.
    Cheng MA; Farmer E; Huang C; Lin J; Hung CF; Wu TC
    Hum Gene Ther; 2018 Sep; 29(9):971-996. PubMed ID: 29316817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
    Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
    Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA vaccines for cervical cancer: from bench to bedside.
    Hung CF; Monie A; Alvarez RD; Wu TC
    Exp Mol Med; 2007 Dec; 39(6):679-89. PubMed ID: 18160838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
    Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
    Trimble CL; Morrow MP; Kraynyak KA; Shen X; Dallas M; Yan J; Edwards L; Parker RL; Denny L; Giffear M; Brown AS; Marcozzi-Pierce K; Shah D; Slager AM; Sylvester AJ; Khan A; Broderick KE; Juba RJ; Herring TA; Boyer J; Lee J; Sardesai NY; Weiner DB; Bagarazzi ML
    Lancet; 2015 Nov; 386(10008):2078-2088. PubMed ID: 26386540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors.
    Diniz MO; Cariri FA; Aps LR; Ferreira LC
    Hum Gene Ther; 2013 Oct; 24(10):861-70. PubMed ID: 24007495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
    Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
    Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Molecular basis of cervical carcinogenesis by high-risk human papillomaviruses].
    Yugawa T; Kiyono T
    Uirusu; 2008 Dec; 58(2):141-54. PubMed ID: 19374192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen.
    Yan J; Reichenbach DK; Corbitt N; Hokey DA; Ramanathan MP; McKinney KA; Weiner DB; Sewell D
    Vaccine; 2009 Jan; 27(3):431-40. PubMed ID: 19022315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination Against Human Papilloma Viruses Leads to a Favorable Cytokine Profile of Specific T Cells.
    Luckau S; Wehrs TP; Brandau S; Horn PA; Lindemann M
    J Immunother; 2016 Oct; 39(8):316-20. PubMed ID: 27548034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
    Bermúdez-Humarán LG; Cortes-Perez NG; Lefèvre F; Guimarães V; Rabot S; Alcocer-Gonzalez JM; Gratadoux JJ; Rodriguez-Padilla C; Tamez-Guerra RS; Corthier G; Gruss A; Langella P
    J Immunol; 2005 Dec; 175(11):7297-302. PubMed ID: 16301635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV
    Dorta-Estremera S; Chin RL; Sierra G; Nicholas C; Yanamandra AV; Nookala SMK; Yang G; Singh S; Curran MA; Sastry KJ
    Cancer Res; 2018 Sep; 78(18):5327-5339. PubMed ID: 30054333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.